Videos

Glenn Tillotson, PhD, explains how inappropriate empiric therapy can drive poor outcomes.

Experts provide community physicians treating HIV with practical advice for screening, diagnosing, and managing patients with HIV.

Kimberly Claeys, PharmD, discusses the need for more data on rapid diagnostics for gram-negative bloodstream infections.

Jason Gallagher, PharmD, FCCP, FIDSA, BCPS, previews his editor-in-chief letter for the June issue.

Ryan K. Shields, PharmD, MS, Contagion®'s Multidrug-Resistant Infections Section Editor, previews the upcoming June issue.

Section Editor, Monica Mahoney, PharmD, shares a preview of the June issue of Contagion.

Thomas Lodise, PharmD, PhD, discusses why "time to clinical response" is a valuable metric to use in clinical studies.

Minh-Hong Nguyen, MD, explains why it's so important to continue developing new antifungal drugs.

Steven Tong, PhD, discusses the next steps for research on combination therapy for MRSA bacteremia.

Vanessa Stevens, PhD, discusses her research on fluoroquinolone and cephalosporin prescribing and rates of Clostridium difficile infections at VA health care facilities.

Ben Berkhout, MD, PhD, discusses his work on the development of a novel curative strategy for HIV-1 infected individuals.

Elizabeth Hirsch, PharmD, and Mélanie Mahoney, PharmD candidate, discuss their poster on Escherichia coli ST131 in Boston vs Minneapolis at ECCMID 2019.

Marin Kollef, MD, discusses recently approved agents targeting antibiotic resistant gram-negative bacteria and what to expect in the next 5 years.

Tristan Ferry, MD, PhD, discusses why there is a need to develop alternatives to treat chronic bone and joint infections.

Laura Shallcross, PhD, discusses how clinicians have “a low threshold” for initiating antibiotics in the emergency department for patients with symptoms similar to a UTI.

Leslie Tari, PhD, discusses Cidara Therapeutics' Cloudbreak antiviral initiatives.

Melanie Nicol, PharmD, PhD, explores how DMPA hormonal contraception affects women's HIV risk.

Brian Woodfall, MD, discusses how long-acting injectables offer a new treatment option for patients with HIV in terms of long-term therapy.

Paul Sax, MD, names the DISCOVER study as one of the highlights of CROI 2019.

Saye Khoo, MD, advocates for a more appropriate, stratified, risk-based approach to prescribing dolutegravir in pregnant women.

Bluma Brenner, PhD, explains the driving factors behind the push for new antiretroviral drugs for HIV treatment.

Brian Woodfall, MD, shares his opinion on some of the biggest advancements in HIV treatment and prevention.

Paul Sax, MD, reacts to the ATLAS and FLAIR studies on long-acting injectable therapy.

Susan Swindells, MBBS, provides an overview of long-acting injectable cabotegravir + rilpivirine for clinicians.

Karin Bosh, PhD, explains why the opioid overdose death rate was higher in 2015 than in 2011 among people with HIV.

Julia Marcus, PhD, MPH, provides advice for health care systems looking to implement a model to identify potential PrEP candidates.

Ava Avalos, MD, details the effects of a dolutegravir-based regimen on pregnancy.

Paul Drain, MD, MPH, explains how point-of-care viral load testing was successful in providing rapid results to patients in a South African-based study.

Kavita Misra, PhD, MPH, explains how health care providers can help prevent PrEP resistance from growing by increasing screening for acute HIV infection.

Julia Marcus, PhD, MPH, discusses the barriers of PrEP use and how current prescribing guidelines are used in clinical practice.